CD69 Antibody (H1.2F3) [Alexa Fluor® 488]

Alexa Fluor (R) products are provided under an intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: (i) in manufacturing; (ii) to provide a service, information, or data in return for payment; (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

CD69, also known as very early activation (VEA) antigen, is a disulfide-linked transmembrane homodimer whose differentially glycosylated subunits range from 35-39 kDa. (1,2) It is a C-type lectin, most closely related to the NKR-P1 and Ly-49 NK cell-activation molecules. (3) CD69 is widely expressed on hematopoietic cells, including lymphocytes, neutrophils and eosinophils. (1-4) Although not detectable on resting lymphocytes, its expression is rapidly (within 2 hours) upregulated upon activation of T, B and NK cells, and neutrophils. (4) Constitutive expression of CD69 on subsets of thymocytes suggests that it may be involved in regulation of developmental events in addition to its role in activation of a variety of hematopoietic cells. (4,5) MAb H1.2F3 augments PMA-induced T-cell proliferation,1,6 and induces redirected lysis of Fc receptor-bearing target cells by NK cells. (7)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Mouse.

We have publications tested in 1 application: FLOW.

Showing Publications 1 - 3 of 3.

Publications using NBP1-28011AF488	Applications	Species
Salman S, Meyers DJ, Wicks EE Et al. HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy J Clin Invest 2022-05-02 [PMID: 35499076] (FLOW, FLOW, Mouse) Details: Citation using the Alexa Fluor 488 version of this antibody.	FLOW, FLOW	Mouse
Samanta D, Huang T, Shah R et al. BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy Cell Rep [PMID: 32846130] (FLOW, Mouse) Details: Citation using the PE format of this antibody.	FLOW	Mouse
Samanta D, Park Y, Ni X et al. Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells Proc. Natl. Acad. Sci. U.S.A. 2018-01-24 [PMID: 29367423] (FLOW, Mouse) Details: This citation used the Alexa Fluor 488 form of this antbody	FLOW	Mouse

Images	Ratings	Applications	Species	Date	Details
	5 reviewed by: Verified Customer	Flow	Mouse	05/03/2019	View Summary Application Flow Cytometry Sample Tested Breast cancer tissue Species Mouse Lot J309-XA18-111318

Array NBP1-28011AF488

• CD69 Antibodies
• CD69 Antibody Pair
• CD69 ELISA Kits
• CD69 Lysate
• CD69 Protein
• CD69 Proteins and Enzymes